Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447]
| Autor: | Ochsenreither, S., Fiedler, W.M., Del Conte, G., Macchini, M., Matos, I., Habel, B., Ahrens-Fath, I., Raspagliesi, F., Lorusso, D., Keilholz, U., Rolling, C., Kebenko, M., Klinghammer, K.F., Saavedra, O., Baumeister, H., Zurlo, A., Garralda, A. |
|---|---|
| Zdroj: | In ESMO Open August 2022 7(4) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|